|
08 Aug 2023 |
Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial
|
|
01 Aug 2023 |
ReAlta Life Sciences Doses First Patient in Phase 2 STAR-Study of RLS-0071 for Hypoxic Ischemic Encephalopathy in Newborns
|
|
30 Jul 2023 |
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
|
|
30 Jul 2023 |
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
|
|
27 Jul 2023 |
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma
|
|
27 Jul 2023 |
Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies
|
|
27 Jul 2023 |
Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies
|
|
26 Jul 2023 |
Amytrx Therapeutics' AMTX-100 Phase 1 Clinical Trial Data Presented at Revolutionizing Atopic Dermatitis Conference
|
|
17 Jul 2023 |
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide
|
|
13 Jul 2023 |
First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation
|
|
10 Jul 2023 |
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
|
|
10 Jul 2023 |
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
|
|
06 Jul 2023 |
Simcha Therapeutics Announces First Patient Dosed in Phase 1/2 Study Evaluating ST-067 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Various Solid Tumors
|
|
03 Jul 2023 |
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
|
|
30 Jun 2023 |
First ten HER2-low patients dosed in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025
|
|
29 Jun 2023 |
Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer
|
|
28 Jun 2023 |
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
|
|
27 Jun 2023 |
Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight
|
|
26 Jun 2023 |
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
|
|
25 Jun 2023 |
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
|
|
24 Jun 2023 |
Sciwind Biosciences to Highlight Positive Clinical Data for GLP-1 Peptide Agonist Ecnoglutide (XW003) at the American Diabetes Association (ADA) 83rd Annual Conference
|
|
24 Jun 2023 |
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)1
|
|
24 Jun 2023 |
Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes
|
|
21 Jun 2023 |
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
|
|
21 Jun 2023 |
Boston Pharmaceuticals Announces Positive Phase 2a Results from Monthly and Bi-weekly Dosing with Investigational BOS-580 NASH Program at EASL 2023
|
